Publications by authors named "I Ferrarini"
Chronic lymphocytic leukemia (CLL) is characterized by an extremely variable clinical course. Although several parameters have been shown to be associated with clinical outcomes in patients with CLL, there remains substantial intragroup clinical heterogeneity in otherwise molecularly and staging homogeneous CLL subgroups. We have recently shown that high catalase (CAT) expression identifies patients with an aggressive clinical course and that higher CAT expression is associated with the presence of the rs1001179 single nucleotide polymorphism (SNP) T allele in the CAT promoter.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the safety and effectiveness of rituximab biosimilars compared to the original rituximab (Mabthera) in 800 patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia across 13 centers in Italy.
- Out of 505 newly diagnosed patients analyzed, 16.8% experienced adverse drug reactions (ADRs), mostly during the first and second infusions, with the common reactions being general disorders and administration site conditions.
- The results indicate that rituximab biosimilars are clinically safe and switching between different biosimilars does not increase adverse events, potentially encouraging wider use and lowering healthcare costs.
Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting.
View Article and Find Full Text PDF